Biomarin Pharmaceutical Inc (BMRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biomarin Pharmaceutical Inc (BMRN) has a cash flow conversion efficiency ratio of 0.036x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($220.65 Million) by net assets ($6.21 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Biomarin Pharmaceutical Inc's balance sheet to measure how much of total assets are equity-financed.
Biomarin Pharmaceutical Inc - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Biomarin Pharmaceutical Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Biomarin Pharmaceutical Inc to evaluate the quality of earnings relative to operating cash generation.
Biomarin Pharmaceutical Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biomarin Pharmaceutical Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gildan Activewear Inc.
TO:GIL
|
-0.081x |
|
Indus Towers Limited
NSE:INDUSTOWER
|
0.219x |
|
Assurant Inc
NYSE:AIZ
|
0.114x |
|
Stifel Financial Corporation
NYSE:SF
|
-0.057x |
|
American Financial Group, Inc.
NYSE:AFG
|
0.101x |
|
Banco Santander (Brasil) S.A.
SA:SANB3
|
0.200x |
|
Bluescope Steel Ltd
AU:BSL
|
0.069x |
|
Sichuan Road & Bridge Group Co Ltd
SHG:600039
|
0.077x |
Annual Cash Flow Conversion Efficiency for Biomarin Pharmaceutical Inc (1998–2025)
The table below shows the annual cash flow conversion efficiency of Biomarin Pharmaceutical Inc from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see BMRN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.09 Billion | $827.99 Million | 0.136x | +34.35% |
| 2024-12-31 | $5.66 Billion | $572.84 Million | 0.101x | +214.78% |
| 2023-12-31 | $4.95 Billion | $159.26 Million | 0.032x | -15.83% |
| 2022-12-31 | $4.60 Billion | $175.90 Million | 0.038x | -46.41% |
| 2021-12-31 | $4.27 Billion | $304.54 Million | 0.071x | +242.98% |
| 2020-12-31 | $4.11 Billion | $85.36 Million | 0.021x | +34.51% |
| 2019-12-31 | $3.12 Billion | $48.26 Million | 0.015x | +127.01% |
| 2018-12-31 | $2.97 Billion | $20.21 Million | 0.007x | +318.38% |
| 2017-12-31 | $2.81 Billion | $-8.76 Million | -0.003x | +96.21% |
| 2016-12-31 | $2.77 Billion | $-227.84 Million | -0.082x | +10.80% |
| 2015-12-31 | $2.40 Billion | $-221.69 Million | -0.092x | -91.85% |
| 2014-12-31 | $1.53 Billion | $-73.54 Million | -0.048x | -8.24% |
| 2013-12-31 | $1.34 Billion | $-59.63 Million | -0.044x | -356.51% |
| 2012-12-31 | $1.02 Billion | $17.61 Million | 0.017x | -28.54% |
| 2011-12-31 | $773.05 Million | $18.75 Million | 0.024x | -7.18% |
| 2010-12-31 | $717.26 Million | $18.75 Million | 0.026x | -90.40% |
| 2009-12-31 | $322.19 Million | $87.73 Million | 0.272x | +921.14% |
| 2008-12-31 | $276.68 Million | $-9.18 Million | -0.033x | +81.95% |
| 2007-12-31 | $187.73 Million | $-34.49 Million | -0.184x | +56.79% |
| 2006-12-31 | $117.80 Million | $-50.09 Million | -0.425x | -152.55% |
| 2005-12-31 | $-77.46 Million | $-62.68 Million | 0.809x | -15.56% |
| 2004-12-31 | $-67.98 Million | $-65.14 Million | 0.958x | +250.99% |
| 2003-12-31 | $117.85 Million | $-74.80 Million | -0.635x | -16.69% |
| 2002-12-31 | $98.54 Million | $-53.59 Million | -0.544x | -276.22% |
| 2001-12-31 | $159.55 Million | $-23.07 Million | -0.145x | +21.54% |
| 2000-12-31 | $69.99 Million | $-12.90 Million | -0.184x | -40.07% |
| 1999-12-31 | $98.38 Million | $-12.94 Million | -0.132x | +52.26% |
| 1998-12-31 | $29.40 Million | $-8.10 Million | -0.276x | -- |
About Biomarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV t… Read more